Status:

COMPLETED

REGENERA Implant in Excised Non-Malignant Breast Lesions

Lead Sponsor:

Tensive SRL

Conditions:

Benign Breast Disease

Eligibility:

FEMALE

20-85 years

Phase:

NA

Brief Summary

The purpose of this First-in-Human pilot study is to evaluate the safety and performance of REGENERA breast implant in a selected cohort of patients with non- malignant breast lesions treated with exc...

Detailed Description

This is a pre-market, single center, interventional, open label, non-comparative, pilot first-in-human study on adult female patients with localized non-malignant breast lesion. This study will includ...

Eligibility Criteria

Inclusion

  • Female patients aged 20-85 years
  • Patients eligible for excision or lumpectomy, as per current surgical guidelines
  • Volume deficit compatible with an implant volume of 70 cc
  • Adequate hematopoietic functions
  • Good general health and mentally sound
  • Confirmation of non-malignant lesion (B2 and B3) with no discordance between biopsy and radiological imaging
  • Patients able and willing to give written informed consent form

Exclusion

  • Pregnant or breastfeeding women or women who have nursed a child three months within enrolment in the study
  • Non-malignant lesions (B2 and B3) with discordance between biopsy and radiological imaging
  • Infection of the surgical site confirmed pre-operatively by clinical examination
  • Acute or chronic severe renal insufficiency (creatinine values \< 180 μmol/L)
  • History of severe asthma or allergies (including to anaesthetics or contrast media)
  • Autoimmune disease
  • Subject with actual concomitant malignancies, lobular neoplasm, metastatic breast carcinoma, sarcoma, malignant phyllodes lesions, or Paget's disease
  • Subject who are known to be carriers of BCRA mutation
  • Inability to undergo MRI or allergy to contrast media
  • Systemic infections in active phase
  • Immunocompromised patients (HIV)
  • Subjects who have participated in another study within the past 3 months
  • Patients who received immunosuppressant therapy in the last 3 months
  • Non-collaborative patients (severe physical disabilities or psychiatric disorders, as per specialist opinion).

Key Trial Info

Start Date :

November 11 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 27 2021

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT04131972

Start Date

November 11 2019

End Date

November 27 2021

Last Update

February 8 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Azienda Ospedaliero Universitaria Pisana

Pisa, Italy, 56126